Insider Selling: Artivion (NYSE:AORT) Director Sells 4,200 Shares of Stock

Artivion, Inc. (NYSE:AORT) Director Elizabeth Hoff sold 4,200 shares of the business’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $45.10, for a total value of $189,420.00. Following the completion of the transaction, the director directly owned 27,189 shares of the company’s stock, valued at approximately $1,226,223.90. The trade was a 13.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Artivion Stock Down 0.4%

Shares of AORT traded down $0.16 during mid-day trading on Wednesday, hitting $44.67. 155,294 shares of the company’s stock were exchanged, compared to its average volume of 433,134. The company has a 50-day simple moving average of $42.77 and a 200 day simple moving average of $36.66. Artivion, Inc. has a 52 week low of $21.97 and a 52 week high of $48.04. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.78 and a quick ratio of 3.48. The company has a market cap of $2.12 billion, a PE ratio of -106.20 and a beta of 1.65.

Artivion (NYSE:AORT) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.14 by $0.02. The firm had revenue of $113.39 million for the quarter, compared to analyst estimates of $110.71 million. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. Artivion’s revenue for the quarter was up 18.9% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. On average, research analysts forecast that Artivion, Inc. will post 0.37 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

AORT has been the subject of several recent research reports. Stifel Nicolaus increased their price target on Artivion from $40.00 to $46.00 and gave the company a “buy” rating in a research note on Monday, September 29th. Citigroup reiterated an “outperform” rating on shares of Artivion in a research note on Friday, October 10th. Wall Street Zen raised shares of Artivion from a “buy” rating to a “strong-buy” rating in a report on Saturday. JMP Securities lifted their price target on Artivion from $42.00 to $47.00 and gave the company a “market outperform” rating in a research report on Friday, October 10th. Finally, Oppenheimer reissued an “outperform” rating and issued a $50.00 price target on shares of Artivion in a research note on Friday, November 7th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Artivion currently has an average rating of “Moderate Buy” and an average price target of $49.11.

Hedge Funds Weigh In On Artivion

A number of large investors have recently made changes to their positions in AORT. Aster Capital Management DIFC Ltd boosted its stake in shares of Artivion by 402.3% during the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after purchasing an additional 519 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Artivion in the 3rd quarter worth about $27,000. MCF Advisors LLC grew its position in shares of Artivion by 109.3% in the first quarter. MCF Advisors LLC now owns 1,176 shares of the company’s stock valued at $29,000 after purchasing an additional 614 shares during the period. Smartleaf Asset Management LLC lifted its holdings in Artivion by 47.7% in the 2nd quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after purchasing an additional 538 shares in the last quarter. Finally, State of Wyoming acquired a new position in Artivion during the third quarter worth $80,000. 86.37% of the stock is owned by hedge funds and other institutional investors.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.